Residual cancer burden index: Difference between revisions

(4 intermediate revisions by the same user not shown)

Line 4:

The [[RCB index]] is defined as:<ref name=pmid17785706>{{cite journal |authors=Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L |title=Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy |journal=J Clin Oncol |volume=25 |issue=28 |pages=4414–22 |date=October 2007 |pmid=17785706 |doi=10.1200/JCO.2007.10.6823 |url=}}</ref>

:<math>RCB = 1.4 \ ( f_{inv} \ d_{prim} )^ {0.17} + \lbrack{ \ 4 \ (1 - 0.75^{LN}) d_{met}} \rbrack ^{0.17}</math>

Where:

:<math>f_{inv} = \text {portion of tumour bed that is viable invasive tumour}</math>

:<math>d_{prim} = \sqrt {d_1 \ d_2}</math>

:<math>\text{LN} = \text {number of lymph nodes with metastatic carcinoma}</math>

:<math>d_{met} = \text {diameter of the largest lymph node metastasis}</math>

The inputs to <math>d_{prim}</math> are:

:<math>d_1 = \text{first in-plane tumour dimension}</math>

:<math>d_1 = \text{second in-plane tumour dimension}</math>

==Interpretation==

The original paper stratified patients into three groups using two cut-points:<ref name=pmid17785706/>

*Low risk (RCB-I): RCB > 0 and < 1.36.

*Intermediate risk (RCB-II): RCB > 1.36 and < 3.28.

*High risk (RCB-III): RCB > 3.28.

If one includes the group without any residual disease, there are four groups: RCB-0, RCB-I, RCB-II, RCB-III.

==See also==

*[[Neoadjuvant therapy]].

*[[Lung cancer after neoadjuvant therapy]].

==References==

@@ Line 4: / Line 4: @@
 The [[RCB index]] is defined as:<ref name=pmid17785706>{{cite journal |authors=Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L |title=Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy |journal=J Clin Oncol |volume=25 |issue=28 |pages=4414–22 |date=October 2007 |pmid=17785706 |doi=10.1200/JCO.2007.10.6823 |url=}}</ref>
 :<math>RCB = 1.4 \ ( f_{inv} \ d_{prim} )^ {0.17} +  \lbrack{ \ 4 \ (1 - 0.75^{LN}) d_{met}} \rbrack ^{0.17}</math>
+Where:
+:<math>f_{inv} = \text {portion of tumour bed that is viable invasive tumour}</math>
+:<math>d_{prim} = \sqrt {d_1 \ d_2}</math>
+:<math>\text{LN} = \text {number of lymph nodes with metastatic carcinoma}</math>
+:<math>d_{met} = \text {diameter of the largest lymph node metastasis}</math>
+The inputs to <math>d_{prim}</math> are:
+:<math>d_1 = \text{first in-plane tumour dimension}</math>
+:<math>d_1 = \text{second in-plane tumour dimension}</math>
+==Interpretation==
+The original paper stratified patients into three groups using two cut-points:<ref name=pmid17785706/>
+*Low risk (RCB-I): RCB > 0 and < 1.36.
+*Intermediate risk (RCB-II): RCB > 1.36 and < 3.28.
+*High risk (RCB-III): RCB > 3.28.
+If one includes the group without any residual disease, there are four groups: RCB-0, RCB-I, RCB-II, RCB-III.
 ==See also==
 *[[Neoadjuvant therapy]].
+*[[Lung cancer after neoadjuvant therapy]].
 ==References==

Residual cancer burden index: Difference between revisions

Navigation menu

Search